Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL

VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL

March 25, 2024

a240322_00.png

a240322_01.png

Previous: Results of a Phase III Clinical Study on Batoclimab of CSPC Published in JAMA Sub-journal

Next: VOLUNTARY ANNOUNCEMENT SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat